Incidence and Survival Patterns of Clear Cell Renal Cell Carcinoma from 2000 to 2017: A SEER Database Analysis

Overview

Journal J Cancer

Specialty Oncology

Date 2025 Feb 24

PMID 39991582

Authors

Sijue Zou

Liwen Cui

Pearl Pai

Yiping Lu

Xiangyang Li

Gang Wang

Wen Huang

Dan Wang

Nikhat Shaikh

Zhangzhe Peng

Zhuoming Peng

Haiyan He

Zhouning Liao

Affiliations

Soon will be listed here.

Abstract

: Clear cell renal cell carcinoma (ccRCC) incidence and death have considerably changed in recent years. Our study aimed to investigate the incidence, survival, and tumor characteristics of ccRCC in the year of diagnosis. : Our study participants were selected from the SEER database (2000-2017). Age-standardized incidence rates were calculated to compare incidence rates across time. In addition, we used Kaplan-Meier curves to calculate overall survival (OS) and Cox proportional hazards models to explore risk factors associated with mortality outcomes in patients with ccRCC. : In the SEER analysis from 2000 to 2017, the increasing trend in age-adjusted incidence of ccRCC has remained relatively stable over the years, increasing from 2.63 per 100,000 in 2000 to 8.79 per 100,000 in 2017. The increase in the incidence of patients at a localized stage plays a decisive role in the overall increase in the incidence of ccRCC. : In the general population, patients diagnosed between 2009-2017 had a higher survival rate than those diagnosed between 2000-2008, which is consistent with all stages of the tumor. The incidence of ccRCC increases steadily with the year of diagnosis, while overall survival has significantly improved.

References

Tao Z, Zhang E, Li L, Zheng J, Zhao Y, Chen X . A united risk model of 11 immune‑related gene pairs and clinical stage for prediction of overall survival in clear cell renal cell carcinoma patients. Bioengineered. 2021; 12(1):4259-4277. PMC: 8806637. DOI: 10.1080/21655979.2021.1955558. View

Wang J, Wen Q, Wang X, Liu C, Zhao K, Li Y . Nomogram for predicting cancer-specific survival of patients with clear-cell renal cell carcinoma: a SEER-based population study. Gen Physiol Biophys. 2022; 41(6):591-601. DOI: 10.4149/gpb_2022040. View

Uemura M, Tomita Y, Miyake H, Hatakeyama S, Kanayama H, Numakura K . Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. Cancer Sci. 2019; 111(3):907-923. PMC: 7060483. DOI: 10.1111/cas.14294. View

Wu Y, Kwon Y, Labib M, Foran D, Singer E . Magnetic Resonance Imaging as a Biomarker for Renal Cell Carcinoma. Dis Markers. 2015; 2015:648495. PMC: 4644550. DOI: 10.1155/2015/648495. View

Motzer R, Powles T, Atkins M, Escudier B, Mcdermott D, Alekseev B . Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncol. 2021; 8(2):275-280. PMC: 8855230. DOI: 10.1001/jamaoncol.2021.5981. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Rampersaud E, Klatte T, Bass G, Patard J, Bensaleh K, Bohm M . The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma. Urol Oncol. 2013; 32(1):30.e9-13. DOI: 10.1016/j.urolonc.2012.10.012. View

Shinagare A, Krajewski K, Jagannathan J, Ramaiya N . Genitourinary imaging: part 2, role of imaging in medical management of advanced renal cell carcinoma. AJR Am J Roentgenol. 2012; 199(5):W554-64. DOI: 10.2214/AJR.12.9233. View

Motzer R, Penkov K, Haanen J, Rini B, Albiges L, Campbell M . Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12):1103-1115. PMC: 6716603. DOI: 10.1056/NEJMoa1816047. View

10.

Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L . Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 2022; 39(3). View

11.

Saad A, Gad M, Al-Husseini M, Ruhban I, Sonbol M, Ho T . Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study. Clin Genitourin Cancer. 2018; 17(1):46-57.e5. PMC: 6348014. DOI: 10.1016/j.clgc.2018.10.002. View

12.

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V . Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(5):706-720. DOI: 10.1093/annonc/mdz056. View

13.

Freifeld Y, Ananthakrishnan L, Margulis V . Imaging for Screening and Surveillance of Patients with Hereditary Forms of Renal Cell Carcinoma. Curr Urol Rep. 2018; 19(10):82. DOI: 10.1007/s11934-018-0829-5. View

14.

Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai K, Devarajan K . Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. J Immunother Cancer. 2019; 7(1):139. PMC: 6540413. DOI: 10.1186/s40425-019-0621-1. View

15.

Motzer R, Rini B, Mcdermott D, Frontera O, Hammers H, Carducci M . Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019; 20(10):1370-1385. PMC: 7497870. DOI: 10.1016/S1470-2045(19)30413-9. View

16.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

17.

Liu Y, Kan Y, Zhang J, Li N, Wang Y . Characteristics of contrast-enhanced ultrasound for diagnosis of solid clear cell renal cell carcinomas ≤4 cm: A meta-analysis. Cancer Med. 2021; 10(23):8288-8299. PMC: 8633224. DOI: 10.1002/cam4.4365. View

18.

Rini B, Plimack E, Stus V, Gafanov R, Hawkins R, Nosov D . Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12):1116-1127. DOI: 10.1056/NEJMoa1816714. View

19.

Yin Q, Xu H, Zhong Y, Ni J, Hu S . Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis. BMC Cancer. 2022; 22(1):163. PMC: 8840296. DOI: 10.1186/s12885-022-09239-3. View

20.

Goebell P, Ivanyi P, Bedke J, Bergmann L, Berthold D, Boegemann M . Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. Future Oncol. 2020; 16(29):2307-2328. DOI: 10.2217/fon-2020-0403. View